Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 19, 2014 06:55 ET | Source: Assembly Biosciences, Inc.

Ventrus Biosciences to Merge With Assembly Pharmaceuticals

~ New Company, Assembly Biosciences, to Focus on First-in Class Technology for Treatment and Potential Cure of Hepatitis B Virus Infection, Affecting 350 Million Worldwide ~ Projected...
April 04, 2014 08:00 ET | Source: Assembly Biosciences, Inc.

Ventrus Biosciences Receives Date for Type B Pre-NDA Meeting With FDA for DOLIZEM (Diltiazem Hydrochloride Cream) in Anal Fissures

NEW YORK, April 4, 2014 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced that,...
February 12, 2014 08:00 ET | Source: Assembly Biosciences, Inc.

Ventrus Biosciences Announces Results From Second Pivotal Phase 3 Trial of Diltiazem Cream (VEN 307) in Patients With Anal Fissure

VEN 307 efficacy as expected; placebo effect greater than anticipated, resulting in no significant difference between treatments Data demonstrate an excellent safety profile Company plans...
November 25, 2013 07:30 ET | Source: Assembly Biosciences, Inc.

Ventrus Biosciences Completes Enrollment of Second Pivotal Phase 3 Trial of Diltiazem Cream (VEN 307) in Patients With Anal Fissure

NEW YORK, Nov. 25, 2013 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS) announced that it has completed patient enrollment and randomization in the second Phase 3 clinical trial of...
September 11, 2013 08:00 ET | Source: Assembly Biosciences, Inc.

Ventrus Biosciences Announces Positive Results From Clinical Dermal Safety and Pharmacokinetic Studies of Diltiazem (VEN 307)

NEW YORK, Sept. 11, 2013 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced...
March 01, 2013 08:00 ET | Source: Assembly Biosciences, Inc.

Ventrus Biosciences Announces Poster Presentation on the Quality of Compounded Topical Diltiazem Hydrochloride Formulations for Anal Fissure at the American Pharmacists Association Meeting

NEW YORK, March 1, 2013 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS) today announced the poster presentation of the results from its study investigating the quality of compounded...
February 11, 2013 14:57 ET | Source: Assembly Biosciences, Inc.

Ventrus Biosciences to Present at the Leerink Swann Global Healthcare Conference

NEW YORK, Feb. 11, 2013 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced that...
February 07, 2013 09:13 ET | Source: Assembly Biosciences, Inc.

Ventrus Biosciences Announces Full Exercise of Overallotment Option by Underwriters

NEW YORK, Feb. 7, 2013 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS) today announced that the underwriter of its previously announced public offering of common stock has exercised in...
January 30, 2013 08:56 ET | Source: Assembly Biosciences, Inc.

Ventrus Biosciences Announces $20 Million Financing

NEW YORK, Jan. 30, 2013 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS) announced today the pricing of concurrent, separate underwritten offerings of (i) 5,800,000 shares of its common...
January 29, 2013 16:19 ET | Source: Assembly Biosciences, Inc.

Ventrus Biosciences Announces Proposed Public Offerings of Common Stock and Series A Convertible Preferred Stock

NEW YORK, Jan. 29, 2013 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS) announced today that it is concurrently offering to sell, subject to market and other conditions, (i) shares of its...